Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP12 | P39900 | 3/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | MMP14 | P50281 | 2/20 | 0.50 |
| ▸ | MMP16 | P51512 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430740 | 0.95 | LOXL2 (0.48) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL4439777 | 0.92 | FFAR1 (0.44) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL5132323 | 0.92 | MMP2 (0.46) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL4430445 | 0.92 | ACLY (0.43) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL4433212 | 0.92 | RXRA (0.43) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL4440857 | 0.92 | MMP2 (0.53) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL4430009 | 0.91 | RXRA (0.45) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL5122402 | 0.91 | MMP2 (0.44) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL5122594 | 0.91 | MMP2 (0.44) | MMP2MMP12MMP8MMP13MMP14 | |
| SCHEMBL5132191 | 0.89 | RXRA (0.54) | MMP2MMP12MMP8MMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121591-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008109697-A2 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221127-A1 | peroxisome proliferator-activated receptor agonists; congestive heart failure, atherosclerosis, arteriosclerosis, obesity, hyperlipidemia, hypoalphalipoproteinemia, Syndrome X, diabetes, insulin resistance | PPARA, PPARG, PPARD | MMP2 2866/4885MMP12 1194/4885MMP8 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.